schliessen

Filtern

 

Bibliotheken

Study of Heart and Renal Protection (SHARP): Randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease

Background Lowering low-density lipoprotein (LDL) cholesterol with statin therapy has been shown to reduce the incidence of atherosclerotic events in many types of patient, but it remains uncertain whether it is of net benefit among people with chronic kidney disease (CKD). Methods Patients with adv... Full description

Journal Title: The American heart journal 2010, Vol.160 (5), p.785-794.e10
Main Author: Group, Sharp Collaborative
Format: Electronic Article Electronic Article
Language: English
Subjects:
Quelle: Alma/SFX Local Collection
Publisher: New York, NY: Mosby, Inc
ID: ISSN: 0002-8703
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_swepub_primary_oai_DiVA_org_uu_304261
title: Study of Heart and Renal Protection (SHARP): Randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease
format: Article
creator:
  • Group, Sharp Collaborative
subjects:
  • Adult
  • Aged
  • Analysis
  • Anticholesteremic Agents - administration & dosage
  • Anticholesteremic Agents - therapeutic use
  • Atherosclerosis - blood
  • Atherosclerosis - etiology
  • Atherosclerosis - prevention & control
  • Azetidines - administration & dosage
  • Azetidines - therapeutic use
  • Biological and medical sciences
  • Cardiology. Vascular system
  • Cardiovascular
  • Cholesterol
  • Cholesterol, LDL - blood
  • Cholesterol, LDL - drug effects
  • Chronic kidney failure
  • Clinical Medicine
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Drug therapy
  • Drug Therapy, Combination
  • Ezetimibe
  • Female
  • Follow-Up Studies
  • Heart attacks
  • Humans
  • Incidence
  • Kidney Failure, Chronic - blood
  • Kidney Failure, Chronic - complications
  • Kidney Failure, Chronic - therapy
  • Kidneys
  • Klinisk medicin
  • Lipids
  • Low density lipoprotein
  • Low density lipoproteins
  • Male
  • Medical and Health Sciences
  • Medical research
  • Medical sciences
  • Medicin och hälsovetenskap
  • Medicine, Experimental
  • Middle Aged
  • Nephrology. Urinary tract diseases
  • Nephropathies. Renovascular diseases. Renal failure
  • Renal Dialysis
  • Renal failure
  • Retrospective Studies
  • Simvastatin - administration & dosage
  • Simvastatin - therapeutic use
  • Treatment Outcome
  • Urinary system involvement in other diseases. Miscellaneous
  • Urologi och njurmedicin
  • Urology and Nephrology
ispartof: The American heart journal, 2010, Vol.160 (5), p.785-794.e10
description: Background Lowering low-density lipoprotein (LDL) cholesterol with statin therapy has been shown to reduce the incidence of atherosclerotic events in many types of patient, but it remains uncertain whether it is of net benefit among people with chronic kidney disease (CKD). Methods Patients with advanced CKD (blood creatinine ≥1.7 mg/dL [≥ 150 μmol/L] in men or ≥1.5 mg/dL [ ≥ 130 μmol/L] in women) with no known history of myocardial infarction or coronary revascularization were randomized in a ratio of 4:4:1 to ezetimibe 10 mg plus simvastatin 20 mg daily versus matching placebo versus simvastatin 20 mg daily (with the latter arm rerandomized at 1 year to ezetimibe 10 mg plus simvastatin 20 mg daily vs placebo). The key outcome will be major atherosclerotic events , defined as the combination of myocardial infarction, coronary death, ischemic stroke, or any revascularization procedure. Results A total of 9,438 CKD patients were randomized, of whom 3,056 were on dialysis. Mean age was 61 years, two thirds were male, one fifth had diabetes mellitus, and one sixth had vascular disease. Compared with either placebo or simvastatin alone, allocation to ezetimibe plus simvastatin was not associated with any excess of myopathy, hepatic toxicity, or biliary complications during the first year of follow-up. Compared with placebo, allocation to ezetimibe 10 mg plus simvastatin 20 mg daily yielded average LDL cholesterol differences of 43 mg/dL (1.10 mmol/L) at 1 year and 33 mg/dL (0.85 mmol/L) at 2.5 years. Follow-up is scheduled to continue until August 2010, when all patients will have been followed for at least 4 years. Conclusions SHARP should provide evidence about the efficacy and safety of lowering LDL cholesterol with the combination of ezetimibe and simvastatin among a wide range of patients with CKD.
language: eng
source: Alma/SFX Local Collection
identifier: ISSN: 0002-8703
fulltext: fulltext
issn:
  • 0002-8703
  • 1097-6744
  • 1097-6744
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.6768317
LOCALfalse
PrimoNMBib
record
control
sourceidgale_swepu
recordidTN_cdi_swepub_primary_oai_DiVA_org_uu_304261
sourceformatXML
sourcesystemPC
galeidA242604346
sourcerecordidA242604346
originalsourceidFETCH-LOGICAL-1588t-715a382c61bac36f7335f58ab7c45662f79a15a65a6d6f6038183f722ce6c7003
addsrcrecordideNp9kl1r1EAUhoMotlZ_gDcyIIJCd52PZJJVEJb6UaFgadXbYXZypnu22cw6M7Gsv8sf6AlbW-hFSSAzyfO-OXPOWxTPBZ8KLvTb1dQuV1PJac-bKRfyQbEv-Kye6LosHxb7nHM5aWqu9oonKa1oq2WjHxd7kqhKarVf_D3PQ7tlwbNjsDEz27fsDHrbsdMYMriMoWevz4_nZ6dv3rEz-hzW-AdaliMSlAOzKUFKLC-BgfekSKNbF64gYn8xLiYt9AnzlnW4CZvRFnvmlqGDlCGGjtl1IHJ2WKqGbWxG6MnkCvOSqBh6dOwS2x62rMUENsHT4pG3XYJn18-D4sfnT9-Pjicn3758PZqfTETVNHlSi8qqRjotFtYp7WulKl81dlG7stJa-npmCdF0t9prrhrRKF9L6UC7mnN1UBzufNMVbIaF2URc27g1waL5iD_nJsQLMwxG8VJqQfjLHU5n_DXQ4cwqDJF6mYyoeKnVTOuGqOmOurAdGOx9yNE6ulpYows9eKT3c0mWvFSkOijETuBiSCmCv6lDcDPmwKwM5cCMOTC8MZQD0ry4LmVYrKG9UfwfPAGvrgGbnO18tL3DdMspLctajC2o7_zcYbZjKqhq7O4t4f1OCTSh3wjRJEeTddBipJSYNuC96g931K5DSoLtLmEL6baxJknDzfkY9THpghZ1NVPqH4Pu92Y
sourcetypeOpen Access Repository
isCDItrue
recordtypearticle
pqid1504639668
display
typearticle
titleStudy of Heart and Renal Protection (SHARP): Randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease
sourceAlma/SFX Local Collection
creatorGroup, Sharp Collaborative
creatorcontribGroup, Sharp Collaborative
descriptionBackground Lowering low-density lipoprotein (LDL) cholesterol with statin therapy has been shown to reduce the incidence of atherosclerotic events in many types of patient, but it remains uncertain whether it is of net benefit among people with chronic kidney disease (CKD). Methods Patients with advanced CKD (blood creatinine ≥1.7 mg/dL [≥ 150 μmol/L] in men or ≥1.5 mg/dL [ ≥ 130 μmol/L] in women) with no known history of myocardial infarction or coronary revascularization were randomized in a ratio of 4:4:1 to ezetimibe 10 mg plus simvastatin 20 mg daily versus matching placebo versus simvastatin 20 mg daily (with the latter arm rerandomized at 1 year to ezetimibe 10 mg plus simvastatin 20 mg daily vs placebo). The key outcome will be major atherosclerotic events , defined as the combination of myocardial infarction, coronary death, ischemic stroke, or any revascularization procedure. Results A total of 9,438 CKD patients were randomized, of whom 3,056 were on dialysis. Mean age was 61 years, two thirds were male, one fifth had diabetes mellitus, and one sixth had vascular disease. Compared with either placebo or simvastatin alone, allocation to ezetimibe plus simvastatin was not associated with any excess of myopathy, hepatic toxicity, or biliary complications during the first year of follow-up. Compared with placebo, allocation to ezetimibe 10 mg plus simvastatin 20 mg daily yielded average LDL cholesterol differences of 43 mg/dL (1.10 mmol/L) at 1 year and 33 mg/dL (0.85 mmol/L) at 2.5 years. Follow-up is scheduled to continue until August 2010, when all patients will have been followed for at least 4 years. Conclusions SHARP should provide evidence about the efficacy and safety of lowering LDL cholesterol with the combination of ezetimibe and simvastatin among a wide range of patients with CKD.
identifier
0ISSN: 0002-8703
1ISSN: 1097-6744
2EISSN: 1097-6744
3DOI: 10.1016/j.ahj.2010.08.012
4PMID: 21095263
5CODEN: AHJOA2
languageeng
publisherNew York, NY: Mosby, Inc
subjectAdult ; Aged ; Analysis ; Anticholesteremic Agents - administration & dosage ; Anticholesteremic Agents - therapeutic use ; Atherosclerosis - blood ; Atherosclerosis - etiology ; Atherosclerosis - prevention & control ; Azetidines - administration & dosage ; Azetidines - therapeutic use ; Biological and medical sciences ; Cardiology. Vascular system ; Cardiovascular ; Cholesterol ; Cholesterol, LDL - blood ; Cholesterol, LDL - drug effects ; Chronic kidney failure ; Clinical Medicine ; Dose-Response Relationship, Drug ; Double-Blind Method ; Drug therapy ; Drug Therapy, Combination ; Ezetimibe ; Female ; Follow-Up Studies ; Heart attacks ; Humans ; Incidence ; Kidney Failure, Chronic - blood ; Kidney Failure, Chronic - complications ; Kidney Failure, Chronic - therapy ; Kidneys ; Klinisk medicin ; Lipids ; Low density lipoprotein ; Low density lipoproteins ; Male ; Medical and Health Sciences ; Medical research ; Medical sciences ; Medicin och hälsovetenskap ; Medicine, Experimental ; Middle Aged ; Nephrology. Urinary tract diseases ; Nephropathies. Renovascular diseases. Renal failure ; Renal Dialysis ; Renal failure ; Retrospective Studies ; Simvastatin - administration & dosage ; Simvastatin - therapeutic use ; Treatment Outcome ; Urinary system involvement in other diseases. Miscellaneous ; Urologi och njurmedicin ; Urology and Nephrology
ispartofThe American heart journal, 2010, Vol.160 (5), p.785-794.e10
rights
0Mosby, Inc.
12010 Mosby, Inc.
22015 INIST-CNRS
3Copyright © 2010 Mosby, Inc. All rights reserved.
4COPYRIGHT 2010 Elsevier B.V.
5Copyright Elsevier Limited Nov 2010
lds50peer_reviewed
oafree_for_read
citedbyFETCH-LOGICAL-1588t-715a382c61bac36f7335f58ab7c45662f79a15a65a6d6f6038183f722ce6c7003
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
thumbnail$$Usyndetics_thumb_exl
backlink
0$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23624710$$DView record in Pascal Francis
1$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21095263$$D View this record in MEDLINE/PubMed
2$$Uhttp://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-304261$$DView record from Swedish Publication Index
search
creatorcontribGroup, Sharp Collaborative
title
0Study of Heart and Renal Protection (SHARP): Randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease
1The American heart journal
addtitleAm Heart J
descriptionBackground Lowering low-density lipoprotein (LDL) cholesterol with statin therapy has been shown to reduce the incidence of atherosclerotic events in many types of patient, but it remains uncertain whether it is of net benefit among people with chronic kidney disease (CKD). Methods Patients with advanced CKD (blood creatinine ≥1.7 mg/dL [≥ 150 μmol/L] in men or ≥1.5 mg/dL [ ≥ 130 μmol/L] in women) with no known history of myocardial infarction or coronary revascularization were randomized in a ratio of 4:4:1 to ezetimibe 10 mg plus simvastatin 20 mg daily versus matching placebo versus simvastatin 20 mg daily (with the latter arm rerandomized at 1 year to ezetimibe 10 mg plus simvastatin 20 mg daily vs placebo). The key outcome will be major atherosclerotic events , defined as the combination of myocardial infarction, coronary death, ischemic stroke, or any revascularization procedure. Results A total of 9,438 CKD patients were randomized, of whom 3,056 were on dialysis. Mean age was 61 years, two thirds were male, one fifth had diabetes mellitus, and one sixth had vascular disease. Compared with either placebo or simvastatin alone, allocation to ezetimibe plus simvastatin was not associated with any excess of myopathy, hepatic toxicity, or biliary complications during the first year of follow-up. Compared with placebo, allocation to ezetimibe 10 mg plus simvastatin 20 mg daily yielded average LDL cholesterol differences of 43 mg/dL (1.10 mmol/L) at 1 year and 33 mg/dL (0.85 mmol/L) at 2.5 years. Follow-up is scheduled to continue until August 2010, when all patients will have been followed for at least 4 years. Conclusions SHARP should provide evidence about the efficacy and safety of lowering LDL cholesterol with the combination of ezetimibe and simvastatin among a wide range of patients with CKD.
subject
0Adult
1Aged
2Analysis
3Anticholesteremic Agents - administration & dosage
4Anticholesteremic Agents - therapeutic use
5Atherosclerosis - blood
6Atherosclerosis - etiology
7Atherosclerosis - prevention & control
8Azetidines - administration & dosage
9Azetidines - therapeutic use
10Biological and medical sciences
11Cardiology. Vascular system
12Cardiovascular
13Cholesterol
14Cholesterol, LDL - blood
15Cholesterol, LDL - drug effects
16Chronic kidney failure
17Clinical Medicine
18Dose-Response Relationship, Drug
19Double-Blind Method
20Drug therapy
21Drug Therapy, Combination
22Ezetimibe
23Female
24Follow-Up Studies
25Heart attacks
26Humans
27Incidence
28Kidney Failure, Chronic - blood
29Kidney Failure, Chronic - complications
30Kidney Failure, Chronic - therapy
31Kidneys
32Klinisk medicin
33Lipids
34Low density lipoprotein
35Low density lipoproteins
36Male
37Medical and Health Sciences
38Medical research
39Medical sciences
40Medicin och hälsovetenskap
41Medicine, Experimental
42Middle Aged
43Nephrology. Urinary tract diseases
44Nephropathies. Renovascular diseases. Renal failure
45Renal Dialysis
46Renal failure
47Retrospective Studies
48Simvastatin - administration & dosage
49Simvastatin - therapeutic use
50Treatment Outcome
51Urinary system involvement in other diseases. Miscellaneous
52Urologi och njurmedicin
53Urology and Nephrology
issn
00002-8703
11097-6744
21097-6744
fulltexttrue
rsrctypearticle
creationdate2010
recordtypearticle
recordideNp9kl1r1EAUhoMotlZ_gDcyIIJCd52PZJJVEJb6UaFgadXbYXZypnu22cw6M7Gsv8sf6AlbW-hFSSAzyfO-OXPOWxTPBZ8KLvTb1dQuV1PJac-bKRfyQbEv-Kye6LosHxb7nHM5aWqu9oonKa1oq2WjHxd7kqhKarVf_D3PQ7tlwbNjsDEz27fsDHrbsdMYMriMoWevz4_nZ6dv3rEz-hzW-AdaliMSlAOzKUFKLC-BgfekSKNbF64gYn8xLiYt9AnzlnW4CZvRFnvmlqGDlCGGjtl1IHJ2WKqGbWxG6MnkCvOSqBh6dOwS2x62rMUENsHT4pG3XYJn18-D4sfnT9-Pjicn3758PZqfTETVNHlSi8qqRjotFtYp7WulKl81dlG7stJa-npmCdF0t9prrhrRKF9L6UC7mnN1UBzufNMVbIaF2URc27g1waL5iD_nJsQLMwxG8VJqQfjLHU5n_DXQ4cwqDJF6mYyoeKnVTOuGqOmOurAdGOx9yNE6ulpYows9eKT3c0mWvFSkOijETuBiSCmCv6lDcDPmwKwM5cCMOTC8MZQD0ry4LmVYrKG9UfwfPAGvrgGbnO18tL3DdMspLctajC2o7_zcYbZjKqhq7O4t4f1OCTSh3wjRJEeTddBipJSYNuC96g931K5DSoLtLmEL6baxJknDzfkY9THpghZ1NVPqH4Pu92Y
startdate2010
enddate2010
creatorGroup, Sharp Collaborative
general
0Mosby, Inc
1Mosby
2Elsevier B.V
3Elsevier Limited
scope
0IQODW
1CGR
2CUY
3CVF
4ECM
5EIF
6NPM
7AAYXX
8CITATION
9BSHEE
103V.
117QO
127RV
137TS
147X7
157XB
1688C
1788E
188AO
198C1
208FD
218FI
228FJ
238FK
248G5
25ABUWG
26AN0
27AZQEC
28BENPR
29DWQXO
30FR3
31FYUFA
32GHDGH
33GNUQQ
34GUQSH
35K9.
36KB0
37M0S
38M0T
39M1P
40M2O
41MBDVC
42NAPCQ
43P64
44PADUT
45PQEST
46PQQKQ
47PQUKI
48PRINS
49Q9U
50ADTPV
51AOWAS
sort
creationdate2010
titleStudy of Heart and Renal Protection (SHARP): Randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease
authorGroup, Sharp Collaborative
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-1588t-715a382c61bac36f7335f58ab7c45662f79a15a65a6d6f6038183f722ce6c7003
rsrctypearticles
prefilterarticles
languageeng
creationdate2010
topic
0Adult
1Aged
2Analysis
3Anticholesteremic Agents - administration & dosage
4Anticholesteremic Agents - therapeutic use
5Atherosclerosis - blood
6Atherosclerosis - etiology
7Atherosclerosis - prevention & control
8Azetidines - administration & dosage
9Azetidines - therapeutic use
10Biological and medical sciences
11Cardiology. Vascular system
12Cardiovascular
13Cholesterol
14Cholesterol, LDL - blood
15Cholesterol, LDL - drug effects
16Chronic kidney failure
17Clinical Medicine
18Dose-Response Relationship, Drug
19Double-Blind Method
20Drug therapy
21Drug Therapy, Combination
22Ezetimibe
23Female
24Follow-Up Studies
25Heart attacks
26Humans
27Incidence
28Kidney Failure, Chronic - blood
29Kidney Failure, Chronic - complications
30Kidney Failure, Chronic - therapy
31Kidneys
32Klinisk medicin
33Lipids
34Low density lipoprotein
35Low density lipoproteins
36Male
37Medical and Health Sciences
38Medical research
39Medical sciences
40Medicin och hälsovetenskap
41Medicine, Experimental
42Middle Aged
43Nephrology. Urinary tract diseases
44Nephropathies. Renovascular diseases. Renal failure
45Renal Dialysis
46Renal failure
47Retrospective Studies
48Simvastatin - administration & dosage
49Simvastatin - therapeutic use
50Treatment Outcome
51Urinary system involvement in other diseases. Miscellaneous
52Urologi och njurmedicin
53Urology and Nephrology
toplevel
0peer_reviewed
1online_resources
creatorcontribGroup, Sharp Collaborative
collection
0Pascal-Francis
1Medline
2MEDLINE
3MEDLINE (Ovid)
4MEDLINE
5MEDLINE
6PubMed
7CrossRef
8Academic OneFile (A&I only)
9ProQuest Central (Corporate)
10Biotechnology Research Abstracts
11Nursing & Allied Health Database
12Physical Education Index
13Health & Medical Collection
14ProQuest Central (purchase pre-March 2016)
15Healthcare Administration Database (Alumni)
16Medical Database (Alumni Edition)
17ProQuest Pharma Collection
18Public Health Database
19Technology Research Database
20Hospital Premium Collection
21Hospital Premium Collection (Alumni Edition)
22ProQuest Central (Alumni) (purchase pre-March 2016)
23Research Library (Alumni Edition)
24ProQuest Central (Alumni Edition)
25British Nursing Database
26ProQuest Central Essentials
27ProQuest Central
28ProQuest Central Korea
29Engineering Research Database
30Health Research Premium Collection
31Health Research Premium Collection (Alumni)
32ProQuest Central Student
33Research Library Prep
34ProQuest Health & Medical Complete (Alumni)
35Nursing & Allied Health Database (Alumni Edition)
36Health & Medical Collection (Alumni Edition)
37Healthcare Administration Database
38Medical Database
39Research Library
40Research Library (Corporate)
41Nursing & Allied Health Premium
42Biotechnology and BioEngineering Abstracts
43Research Library China
44ProQuest One Academic Eastern Edition
45ProQuest One Academic
46ProQuest One Academic UKI Edition
47ProQuest Central China
48ProQuest Central Basic
49SwePub
50SwePub Articles
jtitleThe American heart journal
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
auGroup, Sharp Collaborative
formatjournal
genrearticle
ristypeJOUR
atitleStudy of Heart and Renal Protection (SHARP): Randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease
jtitleThe American heart journal
addtitleAm Heart J
date2010
risdate2010
volume160
issue5
spage785
epage794.e10
pages785-794.e10
issn
00002-8703
11097-6744
eissn1097-6744
codenAHJOA2
abstractBackground Lowering low-density lipoprotein (LDL) cholesterol with statin therapy has been shown to reduce the incidence of atherosclerotic events in many types of patient, but it remains uncertain whether it is of net benefit among people with chronic kidney disease (CKD). Methods Patients with advanced CKD (blood creatinine ≥1.7 mg/dL [≥ 150 μmol/L] in men or ≥1.5 mg/dL [ ≥ 130 μmol/L] in women) with no known history of myocardial infarction or coronary revascularization were randomized in a ratio of 4:4:1 to ezetimibe 10 mg plus simvastatin 20 mg daily versus matching placebo versus simvastatin 20 mg daily (with the latter arm rerandomized at 1 year to ezetimibe 10 mg plus simvastatin 20 mg daily vs placebo). The key outcome will be major atherosclerotic events , defined as the combination of myocardial infarction, coronary death, ischemic stroke, or any revascularization procedure. Results A total of 9,438 CKD patients were randomized, of whom 3,056 were on dialysis. Mean age was 61 years, two thirds were male, one fifth had diabetes mellitus, and one sixth had vascular disease. Compared with either placebo or simvastatin alone, allocation to ezetimibe plus simvastatin was not associated with any excess of myopathy, hepatic toxicity, or biliary complications during the first year of follow-up. Compared with placebo, allocation to ezetimibe 10 mg plus simvastatin 20 mg daily yielded average LDL cholesterol differences of 43 mg/dL (1.10 mmol/L) at 1 year and 33 mg/dL (0.85 mmol/L) at 2.5 years. Follow-up is scheduled to continue until August 2010, when all patients will have been followed for at least 4 years. Conclusions SHARP should provide evidence about the efficacy and safety of lowering LDL cholesterol with the combination of ezetimibe and simvastatin among a wide range of patients with CKD.
copNew York, NY
pubMosby, Inc
pmid21095263
doi10.1016/j.ahj.2010.08.012
oafree_for_read